Medical Care
Global Neoantigen Peptides Manufacturing Market Research Report 2025
- May 12, 25
- ID: 236267
- Pages: 88
- Figures: 86
- Views: 1
The global market for Neoantigen Peptides Manufacturing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Neoantigen Peptides Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neoantigen Peptides Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Neoantigen Peptides Manufacturing in Pharmaceutical/Vaccine Developer Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Neoantigen Peptides Manufacturing include Cpc Scientific Inc, Polypeptide Group, Genscript Biotech, Kaneka Eurogentec SA, Vivitide, Almac, Bcn Peptides, Creative Peptides, Pepscan, Provepharm, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neoantigen Peptides Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neoantigen Peptides Manufacturing.
The Neoantigen Peptides Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neoantigen Peptides Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neoantigen Peptides Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cpc Scientific Inc
Polypeptide Group
Genscript Biotech
Kaneka Eurogentec SA
Vivitide
Almac
Bcn Peptides
Creative Peptides
Pepscan
Provepharm
Creosalus
Gyros Protein Technologies
Anaspec
Segment by Type
Olid Phase Synthesis
Solution Phase Synthesis
Segment by Application
Pharmaceutical/Vaccine Developer Companies
Contract Research Organizations (CRO)
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neoantigen Peptides Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Neoantigen Peptides Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neoantigen Peptides Manufacturing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Neoantigen Peptides Manufacturing in Pharmaceutical/Vaccine Developer Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Neoantigen Peptides Manufacturing include Cpc Scientific Inc, Polypeptide Group, Genscript Biotech, Kaneka Eurogentec SA, Vivitide, Almac, Bcn Peptides, Creative Peptides, Pepscan, Provepharm, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neoantigen Peptides Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neoantigen Peptides Manufacturing.
The Neoantigen Peptides Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neoantigen Peptides Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neoantigen Peptides Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cpc Scientific Inc
Polypeptide Group
Genscript Biotech
Kaneka Eurogentec SA
Vivitide
Almac
Bcn Peptides
Creative Peptides
Pepscan
Provepharm
Creosalus
Gyros Protein Technologies
Anaspec
Segment by Type
Olid Phase Synthesis
Solution Phase Synthesis
Segment by Application
Pharmaceutical/Vaccine Developer Companies
Contract Research Organizations (CRO)
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neoantigen Peptides Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Peptides Manufacturing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Olid Phase Synthesis
1.2.3 Solution Phase Synthesis
1.3 Market by Application
1.3.1 Global Neoantigen Peptides Manufacturing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical/Vaccine Developer Companies
1.3.3 Contract Research Organizations (CRO)
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Peptides Manufacturing Market Perspective (2020-2031)
2.2 Global Neoantigen Peptides Manufacturing Growth Trends by Region
2.2.1 Global Neoantigen Peptides Manufacturing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neoantigen Peptides Manufacturing Historic Market Size by Region (2020-2025)
2.2.3 Neoantigen Peptides Manufacturing Forecasted Market Size by Region (2026-2031)
2.3 Neoantigen Peptides Manufacturing Market Dynamics
2.3.1 Neoantigen Peptides Manufacturing Industry Trends
2.3.2 Neoantigen Peptides Manufacturing Market Drivers
2.3.3 Neoantigen Peptides Manufacturing Market Challenges
2.3.4 Neoantigen Peptides Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Peptides Manufacturing Players by Revenue
3.1.1 Global Top Neoantigen Peptides Manufacturing Players by Revenue (2020-2025)
3.1.2 Global Neoantigen Peptides Manufacturing Revenue Market Share by Players (2020-2025)
3.2 Global Neoantigen Peptides Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neoantigen Peptides Manufacturing Revenue
3.4 Global Neoantigen Peptides Manufacturing Market Concentration Ratio
3.4.1 Global Neoantigen Peptides Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Peptides Manufacturing Revenue in 2024
3.5 Global Key Players of Neoantigen Peptides Manufacturing Head office and Area Served
3.6 Global Key Players of Neoantigen Peptides Manufacturing, Product and Application
3.7 Global Key Players of Neoantigen Peptides Manufacturing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Peptides Manufacturing Breakdown Data by Type
4.1 Global Neoantigen Peptides Manufacturing Historic Market Size by Type (2020-2025)
4.2 Global Neoantigen Peptides Manufacturing Forecasted Market Size by Type (2026-2031)
5 Neoantigen Peptides Manufacturing Breakdown Data by Application
5.1 Global Neoantigen Peptides Manufacturing Historic Market Size by Application (2020-2025)
5.2 Global Neoantigen Peptides Manufacturing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neoantigen Peptides Manufacturing Market Size (2020-2031)
6.2 North America Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
6.4 North America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neoantigen Peptides Manufacturing Market Size (2020-2031)
7.2 Europe Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
7.4 Europe Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Peptides Manufacturing Market Size (2020-2031)
8.2 Asia-Pacific Neoantigen Peptides Manufacturing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2020-2025)
8.4 Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neoantigen Peptides Manufacturing Market Size (2020-2031)
9.2 Latin America Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
9.4 Latin America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Peptides Manufacturing Market Size (2020-2031)
10.2 Middle East & Africa Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
10.4 Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cpc Scientific Inc
11.1.1 Cpc Scientific Inc Company Details
11.1.2 Cpc Scientific Inc Business Overview
11.1.3 Cpc Scientific Inc Neoantigen Peptides Manufacturing Introduction
11.1.4 Cpc Scientific Inc Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.1.5 Cpc Scientific Inc Recent Development
11.2 Polypeptide Group
11.2.1 Polypeptide Group Company Details
11.2.2 Polypeptide Group Business Overview
11.2.3 Polypeptide Group Neoantigen Peptides Manufacturing Introduction
11.2.4 Polypeptide Group Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.2.5 Polypeptide Group Recent Development
11.3 Genscript Biotech
11.3.1 Genscript Biotech Company Details
11.3.2 Genscript Biotech Business Overview
11.3.3 Genscript Biotech Neoantigen Peptides Manufacturing Introduction
11.3.4 Genscript Biotech Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.3.5 Genscript Biotech Recent Development
11.4 Kaneka Eurogentec SA
11.4.1 Kaneka Eurogentec SA Company Details
11.4.2 Kaneka Eurogentec SA Business Overview
11.4.3 Kaneka Eurogentec SA Neoantigen Peptides Manufacturing Introduction
11.4.4 Kaneka Eurogentec SA Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.4.5 Kaneka Eurogentec SA Recent Development
11.5 Vivitide
11.5.1 Vivitide Company Details
11.5.2 Vivitide Business Overview
11.5.3 Vivitide Neoantigen Peptides Manufacturing Introduction
11.5.4 Vivitide Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.5.5 Vivitide Recent Development
11.6 Almac
11.6.1 Almac Company Details
11.6.2 Almac Business Overview
11.6.3 Almac Neoantigen Peptides Manufacturing Introduction
11.6.4 Almac Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.6.5 Almac Recent Development
11.7 Bcn Peptides
11.7.1 Bcn Peptides Company Details
11.7.2 Bcn Peptides Business Overview
11.7.3 Bcn Peptides Neoantigen Peptides Manufacturing Introduction
11.7.4 Bcn Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.7.5 Bcn Peptides Recent Development
11.8 Creative Peptides
11.8.1 Creative Peptides Company Details
11.8.2 Creative Peptides Business Overview
11.8.3 Creative Peptides Neoantigen Peptides Manufacturing Introduction
11.8.4 Creative Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.8.5 Creative Peptides Recent Development
11.9 Pepscan
11.9.1 Pepscan Company Details
11.9.2 Pepscan Business Overview
11.9.3 Pepscan Neoantigen Peptides Manufacturing Introduction
11.9.4 Pepscan Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.9.5 Pepscan Recent Development
11.10 Provepharm
11.10.1 Provepharm Company Details
11.10.2 Provepharm Business Overview
11.10.3 Provepharm Neoantigen Peptides Manufacturing Introduction
11.10.4 Provepharm Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.10.5 Provepharm Recent Development
11.11 Creosalus
11.11.1 Creosalus Company Details
11.11.2 Creosalus Business Overview
11.11.3 Creosalus Neoantigen Peptides Manufacturing Introduction
11.11.4 Creosalus Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.11.5 Creosalus Recent Development
11.12 Gyros Protein Technologies
11.12.1 Gyros Protein Technologies Company Details
11.12.2 Gyros Protein Technologies Business Overview
11.12.3 Gyros Protein Technologies Neoantigen Peptides Manufacturing Introduction
11.12.4 Gyros Protein Technologies Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.12.5 Gyros Protein Technologies Recent Development
11.13 Anaspec
11.13.1 Anaspec Company Details
11.13.2 Anaspec Business Overview
11.13.3 Anaspec Neoantigen Peptides Manufacturing Introduction
11.13.4 Anaspec Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.13.5 Anaspec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Peptides Manufacturing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Olid Phase Synthesis
1.2.3 Solution Phase Synthesis
1.3 Market by Application
1.3.1 Global Neoantigen Peptides Manufacturing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical/Vaccine Developer Companies
1.3.3 Contract Research Organizations (CRO)
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Peptides Manufacturing Market Perspective (2020-2031)
2.2 Global Neoantigen Peptides Manufacturing Growth Trends by Region
2.2.1 Global Neoantigen Peptides Manufacturing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neoantigen Peptides Manufacturing Historic Market Size by Region (2020-2025)
2.2.3 Neoantigen Peptides Manufacturing Forecasted Market Size by Region (2026-2031)
2.3 Neoantigen Peptides Manufacturing Market Dynamics
2.3.1 Neoantigen Peptides Manufacturing Industry Trends
2.3.2 Neoantigen Peptides Manufacturing Market Drivers
2.3.3 Neoantigen Peptides Manufacturing Market Challenges
2.3.4 Neoantigen Peptides Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Peptides Manufacturing Players by Revenue
3.1.1 Global Top Neoantigen Peptides Manufacturing Players by Revenue (2020-2025)
3.1.2 Global Neoantigen Peptides Manufacturing Revenue Market Share by Players (2020-2025)
3.2 Global Neoantigen Peptides Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neoantigen Peptides Manufacturing Revenue
3.4 Global Neoantigen Peptides Manufacturing Market Concentration Ratio
3.4.1 Global Neoantigen Peptides Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Peptides Manufacturing Revenue in 2024
3.5 Global Key Players of Neoantigen Peptides Manufacturing Head office and Area Served
3.6 Global Key Players of Neoantigen Peptides Manufacturing, Product and Application
3.7 Global Key Players of Neoantigen Peptides Manufacturing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Peptides Manufacturing Breakdown Data by Type
4.1 Global Neoantigen Peptides Manufacturing Historic Market Size by Type (2020-2025)
4.2 Global Neoantigen Peptides Manufacturing Forecasted Market Size by Type (2026-2031)
5 Neoantigen Peptides Manufacturing Breakdown Data by Application
5.1 Global Neoantigen Peptides Manufacturing Historic Market Size by Application (2020-2025)
5.2 Global Neoantigen Peptides Manufacturing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neoantigen Peptides Manufacturing Market Size (2020-2031)
6.2 North America Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
6.4 North America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neoantigen Peptides Manufacturing Market Size (2020-2031)
7.2 Europe Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
7.4 Europe Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Peptides Manufacturing Market Size (2020-2031)
8.2 Asia-Pacific Neoantigen Peptides Manufacturing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2020-2025)
8.4 Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neoantigen Peptides Manufacturing Market Size (2020-2031)
9.2 Latin America Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
9.4 Latin America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Peptides Manufacturing Market Size (2020-2031)
10.2 Middle East & Africa Neoantigen Peptides Manufacturing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2020-2025)
10.4 Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cpc Scientific Inc
11.1.1 Cpc Scientific Inc Company Details
11.1.2 Cpc Scientific Inc Business Overview
11.1.3 Cpc Scientific Inc Neoantigen Peptides Manufacturing Introduction
11.1.4 Cpc Scientific Inc Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.1.5 Cpc Scientific Inc Recent Development
11.2 Polypeptide Group
11.2.1 Polypeptide Group Company Details
11.2.2 Polypeptide Group Business Overview
11.2.3 Polypeptide Group Neoantigen Peptides Manufacturing Introduction
11.2.4 Polypeptide Group Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.2.5 Polypeptide Group Recent Development
11.3 Genscript Biotech
11.3.1 Genscript Biotech Company Details
11.3.2 Genscript Biotech Business Overview
11.3.3 Genscript Biotech Neoantigen Peptides Manufacturing Introduction
11.3.4 Genscript Biotech Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.3.5 Genscript Biotech Recent Development
11.4 Kaneka Eurogentec SA
11.4.1 Kaneka Eurogentec SA Company Details
11.4.2 Kaneka Eurogentec SA Business Overview
11.4.3 Kaneka Eurogentec SA Neoantigen Peptides Manufacturing Introduction
11.4.4 Kaneka Eurogentec SA Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.4.5 Kaneka Eurogentec SA Recent Development
11.5 Vivitide
11.5.1 Vivitide Company Details
11.5.2 Vivitide Business Overview
11.5.3 Vivitide Neoantigen Peptides Manufacturing Introduction
11.5.4 Vivitide Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.5.5 Vivitide Recent Development
11.6 Almac
11.6.1 Almac Company Details
11.6.2 Almac Business Overview
11.6.3 Almac Neoantigen Peptides Manufacturing Introduction
11.6.4 Almac Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.6.5 Almac Recent Development
11.7 Bcn Peptides
11.7.1 Bcn Peptides Company Details
11.7.2 Bcn Peptides Business Overview
11.7.3 Bcn Peptides Neoantigen Peptides Manufacturing Introduction
11.7.4 Bcn Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.7.5 Bcn Peptides Recent Development
11.8 Creative Peptides
11.8.1 Creative Peptides Company Details
11.8.2 Creative Peptides Business Overview
11.8.3 Creative Peptides Neoantigen Peptides Manufacturing Introduction
11.8.4 Creative Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.8.5 Creative Peptides Recent Development
11.9 Pepscan
11.9.1 Pepscan Company Details
11.9.2 Pepscan Business Overview
11.9.3 Pepscan Neoantigen Peptides Manufacturing Introduction
11.9.4 Pepscan Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.9.5 Pepscan Recent Development
11.10 Provepharm
11.10.1 Provepharm Company Details
11.10.2 Provepharm Business Overview
11.10.3 Provepharm Neoantigen Peptides Manufacturing Introduction
11.10.4 Provepharm Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.10.5 Provepharm Recent Development
11.11 Creosalus
11.11.1 Creosalus Company Details
11.11.2 Creosalus Business Overview
11.11.3 Creosalus Neoantigen Peptides Manufacturing Introduction
11.11.4 Creosalus Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.11.5 Creosalus Recent Development
11.12 Gyros Protein Technologies
11.12.1 Gyros Protein Technologies Company Details
11.12.2 Gyros Protein Technologies Business Overview
11.12.3 Gyros Protein Technologies Neoantigen Peptides Manufacturing Introduction
11.12.4 Gyros Protein Technologies Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.12.5 Gyros Protein Technologies Recent Development
11.13 Anaspec
11.13.1 Anaspec Company Details
11.13.2 Anaspec Business Overview
11.13.3 Anaspec Neoantigen Peptides Manufacturing Introduction
11.13.4 Anaspec Revenue in Neoantigen Peptides Manufacturing Business (2020-2025)
11.13.5 Anaspec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Neoantigen Peptides Manufacturing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Olid Phase Synthesis
Table 3. Key Players of Solution Phase Synthesis
Table 4. Global Neoantigen Peptides Manufacturing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Neoantigen Peptides Manufacturing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Neoantigen Peptides Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Neoantigen Peptides Manufacturing Market Share by Region (2020-2025)
Table 8. Global Neoantigen Peptides Manufacturing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Neoantigen Peptides Manufacturing Market Share by Region (2026-2031)
Table 10. Neoantigen Peptides Manufacturing Market Trends
Table 11. Neoantigen Peptides Manufacturing Market Drivers
Table 12. Neoantigen Peptides Manufacturing Market Challenges
Table 13. Neoantigen Peptides Manufacturing Market Restraints
Table 14. Global Neoantigen Peptides Manufacturing Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Neoantigen Peptides Manufacturing Market Share by Players (2020-2025)
Table 16. Global Top Neoantigen Peptides Manufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Peptides Manufacturing as of 2024)
Table 17. Ranking of Global Top Neoantigen Peptides Manufacturing Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Neoantigen Peptides Manufacturing Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Neoantigen Peptides Manufacturing, Headquarters and Area Served
Table 20. Global Key Players of Neoantigen Peptides Manufacturing, Product and Application
Table 21. Global Key Players of Neoantigen Peptides Manufacturing, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Peptides Manufacturing Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Neoantigen Peptides Manufacturing Revenue Market Share by Type (2020-2025)
Table 25. Global Neoantigen Peptides Manufacturing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Neoantigen Peptides Manufacturing Revenue Market Share by Type (2026-2031)
Table 27. Global Neoantigen Peptides Manufacturing Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Neoantigen Peptides Manufacturing Revenue Market Share by Application (2020-2025)
Table 29. Global Neoantigen Peptides Manufacturing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Neoantigen Peptides Manufacturing Revenue Market Share by Application (2026-2031)
Table 31. North America Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Neoantigen Peptides Manufacturing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 46. Cpc Scientific Inc Company Details
Table 47. Cpc Scientific Inc Business Overview
Table 48. Cpc Scientific Inc Neoantigen Peptides Manufacturing Product
Table 49. Cpc Scientific Inc Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 50. Cpc Scientific Inc Recent Development
Table 51. Polypeptide Group Company Details
Table 52. Polypeptide Group Business Overview
Table 53. Polypeptide Group Neoantigen Peptides Manufacturing Product
Table 54. Polypeptide Group Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 55. Polypeptide Group Recent Development
Table 56. Genscript Biotech Company Details
Table 57. Genscript Biotech Business Overview
Table 58. Genscript Biotech Neoantigen Peptides Manufacturing Product
Table 59. Genscript Biotech Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 60. Genscript Biotech Recent Development
Table 61. Kaneka Eurogentec SA Company Details
Table 62. Kaneka Eurogentec SA Business Overview
Table 63. Kaneka Eurogentec SA Neoantigen Peptides Manufacturing Product
Table 64. Kaneka Eurogentec SA Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 65. Kaneka Eurogentec SA Recent Development
Table 66. Vivitide Company Details
Table 67. Vivitide Business Overview
Table 68. Vivitide Neoantigen Peptides Manufacturing Product
Table 69. Vivitide Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 70. Vivitide Recent Development
Table 71. Almac Company Details
Table 72. Almac Business Overview
Table 73. Almac Neoantigen Peptides Manufacturing Product
Table 74. Almac Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 75. Almac Recent Development
Table 76. Bcn Peptides Company Details
Table 77. Bcn Peptides Business Overview
Table 78. Bcn Peptides Neoantigen Peptides Manufacturing Product
Table 79. Bcn Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 80. Bcn Peptides Recent Development
Table 81. Creative Peptides Company Details
Table 82. Creative Peptides Business Overview
Table 83. Creative Peptides Neoantigen Peptides Manufacturing Product
Table 84. Creative Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 85. Creative Peptides Recent Development
Table 86. Pepscan Company Details
Table 87. Pepscan Business Overview
Table 88. Pepscan Neoantigen Peptides Manufacturing Product
Table 89. Pepscan Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 90. Pepscan Recent Development
Table 91. Provepharm Company Details
Table 92. Provepharm Business Overview
Table 93. Provepharm Neoantigen Peptides Manufacturing Product
Table 94. Provepharm Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 95. Provepharm Recent Development
Table 96. Creosalus Company Details
Table 97. Creosalus Business Overview
Table 98. Creosalus Neoantigen Peptides Manufacturing Product
Table 99. Creosalus Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 100. Creosalus Recent Development
Table 101. Gyros Protein Technologies Company Details
Table 102. Gyros Protein Technologies Business Overview
Table 103. Gyros Protein Technologies Neoantigen Peptides Manufacturing Product
Table 104. Gyros Protein Technologies Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 105. Gyros Protein Technologies Recent Development
Table 106. Anaspec Company Details
Table 107. Anaspec Business Overview
Table 108. Anaspec Neoantigen Peptides Manufacturing Product
Table 109. Anaspec Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 110. Anaspec Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Neoantigen Peptides Manufacturing Picture
Figure 2. Global Neoantigen Peptides Manufacturing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neoantigen Peptides Manufacturing Market Share by Type: 2024 VS 2031
Figure 4. Olid Phase Synthesis Features
Figure 5. Solution Phase Synthesis Features
Figure 6. Global Neoantigen Peptides Manufacturing Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Neoantigen Peptides Manufacturing Market Share by Application: 2024 VS 2031
Figure 8. Pharmaceutical/Vaccine Developer Companies Case Studies
Figure 9. Contract Research Organizations (CRO) Case Studies
Figure 10. Others Case Studies
Figure 11. Neoantigen Peptides Manufacturing Report Years Considered
Figure 12. Global Neoantigen Peptides Manufacturing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Neoantigen Peptides Manufacturing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Neoantigen Peptides Manufacturing Market Share by Region: 2024 VS 2031
Figure 15. Global Neoantigen Peptides Manufacturing Market Share by Players in 2024
Figure 16. Global Top Neoantigen Peptides Manufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Peptides Manufacturing as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Neoantigen Peptides Manufacturing Revenue in 2024
Figure 18. North America Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 20. United States Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 24. Germany Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Neoantigen Peptides Manufacturing Market Share by Region (2020-2031)
Figure 32. China Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 40. Mexico Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 44. Turkey Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Cpc Scientific Inc Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 48. Polypeptide Group Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 49. Genscript Biotech Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 50. Kaneka Eurogentec SA Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 51. Vivitide Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 52. Almac Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 53. Bcn Peptides Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 54. Creative Peptides Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 55. Pepscan Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 56. Provepharm Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 57. Creosalus Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 58. Gyros Protein Technologies Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 59. Anaspec Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Neoantigen Peptides Manufacturing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Olid Phase Synthesis
Table 3. Key Players of Solution Phase Synthesis
Table 4. Global Neoantigen Peptides Manufacturing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Neoantigen Peptides Manufacturing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Neoantigen Peptides Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Neoantigen Peptides Manufacturing Market Share by Region (2020-2025)
Table 8. Global Neoantigen Peptides Manufacturing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Neoantigen Peptides Manufacturing Market Share by Region (2026-2031)
Table 10. Neoantigen Peptides Manufacturing Market Trends
Table 11. Neoantigen Peptides Manufacturing Market Drivers
Table 12. Neoantigen Peptides Manufacturing Market Challenges
Table 13. Neoantigen Peptides Manufacturing Market Restraints
Table 14. Global Neoantigen Peptides Manufacturing Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Neoantigen Peptides Manufacturing Market Share by Players (2020-2025)
Table 16. Global Top Neoantigen Peptides Manufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Peptides Manufacturing as of 2024)
Table 17. Ranking of Global Top Neoantigen Peptides Manufacturing Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Neoantigen Peptides Manufacturing Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Neoantigen Peptides Manufacturing, Headquarters and Area Served
Table 20. Global Key Players of Neoantigen Peptides Manufacturing, Product and Application
Table 21. Global Key Players of Neoantigen Peptides Manufacturing, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Peptides Manufacturing Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Neoantigen Peptides Manufacturing Revenue Market Share by Type (2020-2025)
Table 25. Global Neoantigen Peptides Manufacturing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Neoantigen Peptides Manufacturing Revenue Market Share by Type (2026-2031)
Table 27. Global Neoantigen Peptides Manufacturing Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Neoantigen Peptides Manufacturing Revenue Market Share by Application (2020-2025)
Table 29. Global Neoantigen Peptides Manufacturing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Neoantigen Peptides Manufacturing Revenue Market Share by Application (2026-2031)
Table 31. North America Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Neoantigen Peptides Manufacturing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Neoantigen Peptides Manufacturing Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Neoantigen Peptides Manufacturing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Neoantigen Peptides Manufacturing Market Size by Country (2026-2031) & (US$ Million)
Table 46. Cpc Scientific Inc Company Details
Table 47. Cpc Scientific Inc Business Overview
Table 48. Cpc Scientific Inc Neoantigen Peptides Manufacturing Product
Table 49. Cpc Scientific Inc Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 50. Cpc Scientific Inc Recent Development
Table 51. Polypeptide Group Company Details
Table 52. Polypeptide Group Business Overview
Table 53. Polypeptide Group Neoantigen Peptides Manufacturing Product
Table 54. Polypeptide Group Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 55. Polypeptide Group Recent Development
Table 56. Genscript Biotech Company Details
Table 57. Genscript Biotech Business Overview
Table 58. Genscript Biotech Neoantigen Peptides Manufacturing Product
Table 59. Genscript Biotech Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 60. Genscript Biotech Recent Development
Table 61. Kaneka Eurogentec SA Company Details
Table 62. Kaneka Eurogentec SA Business Overview
Table 63. Kaneka Eurogentec SA Neoantigen Peptides Manufacturing Product
Table 64. Kaneka Eurogentec SA Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 65. Kaneka Eurogentec SA Recent Development
Table 66. Vivitide Company Details
Table 67. Vivitide Business Overview
Table 68. Vivitide Neoantigen Peptides Manufacturing Product
Table 69. Vivitide Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 70. Vivitide Recent Development
Table 71. Almac Company Details
Table 72. Almac Business Overview
Table 73. Almac Neoantigen Peptides Manufacturing Product
Table 74. Almac Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 75. Almac Recent Development
Table 76. Bcn Peptides Company Details
Table 77. Bcn Peptides Business Overview
Table 78. Bcn Peptides Neoantigen Peptides Manufacturing Product
Table 79. Bcn Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 80. Bcn Peptides Recent Development
Table 81. Creative Peptides Company Details
Table 82. Creative Peptides Business Overview
Table 83. Creative Peptides Neoantigen Peptides Manufacturing Product
Table 84. Creative Peptides Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 85. Creative Peptides Recent Development
Table 86. Pepscan Company Details
Table 87. Pepscan Business Overview
Table 88. Pepscan Neoantigen Peptides Manufacturing Product
Table 89. Pepscan Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 90. Pepscan Recent Development
Table 91. Provepharm Company Details
Table 92. Provepharm Business Overview
Table 93. Provepharm Neoantigen Peptides Manufacturing Product
Table 94. Provepharm Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 95. Provepharm Recent Development
Table 96. Creosalus Company Details
Table 97. Creosalus Business Overview
Table 98. Creosalus Neoantigen Peptides Manufacturing Product
Table 99. Creosalus Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 100. Creosalus Recent Development
Table 101. Gyros Protein Technologies Company Details
Table 102. Gyros Protein Technologies Business Overview
Table 103. Gyros Protein Technologies Neoantigen Peptides Manufacturing Product
Table 104. Gyros Protein Technologies Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 105. Gyros Protein Technologies Recent Development
Table 106. Anaspec Company Details
Table 107. Anaspec Business Overview
Table 108. Anaspec Neoantigen Peptides Manufacturing Product
Table 109. Anaspec Revenue in Neoantigen Peptides Manufacturing Business (2020-2025) & (US$ Million)
Table 110. Anaspec Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Neoantigen Peptides Manufacturing Picture
Figure 2. Global Neoantigen Peptides Manufacturing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neoantigen Peptides Manufacturing Market Share by Type: 2024 VS 2031
Figure 4. Olid Phase Synthesis Features
Figure 5. Solution Phase Synthesis Features
Figure 6. Global Neoantigen Peptides Manufacturing Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Neoantigen Peptides Manufacturing Market Share by Application: 2024 VS 2031
Figure 8. Pharmaceutical/Vaccine Developer Companies Case Studies
Figure 9. Contract Research Organizations (CRO) Case Studies
Figure 10. Others Case Studies
Figure 11. Neoantigen Peptides Manufacturing Report Years Considered
Figure 12. Global Neoantigen Peptides Manufacturing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Neoantigen Peptides Manufacturing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Neoantigen Peptides Manufacturing Market Share by Region: 2024 VS 2031
Figure 15. Global Neoantigen Peptides Manufacturing Market Share by Players in 2024
Figure 16. Global Top Neoantigen Peptides Manufacturing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Peptides Manufacturing as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Neoantigen Peptides Manufacturing Revenue in 2024
Figure 18. North America Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 20. United States Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 24. Germany Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Neoantigen Peptides Manufacturing Market Share by Region (2020-2031)
Figure 32. China Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 40. Mexico Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Neoantigen Peptides Manufacturing Market Share by Country (2020-2031)
Figure 44. Turkey Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Neoantigen Peptides Manufacturing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Cpc Scientific Inc Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 48. Polypeptide Group Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 49. Genscript Biotech Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 50. Kaneka Eurogentec SA Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 51. Vivitide Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 52. Almac Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 53. Bcn Peptides Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 54. Creative Peptides Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 55. Pepscan Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 56. Provepharm Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 57. Creosalus Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 58. Gyros Protein Technologies Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 59. Anaspec Revenue Growth Rate in Neoantigen Peptides Manufacturing Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Krypton Flash Lamp Market Research Report 2025
May 12, 25
Global IR Halogen Lamp Market Research Report 2025
May 12, 25
Global Halogen IR Lamp Market Research Report 2025
May 12, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232